openPR Logo
Press release

Hematological Malignancies Market Research Report by Key Players Analysis 2024

09-18-2017 09:16 AM CET | Health & Medicine

Press release from: Transparency Market Research

Hematological Malignancies Market

Hematological Malignancies Market

The global market for hematological malignancies offered an opportunity worth US$27.4 bn in 2015. Rising at a 7.50% CAGR between 2016 and 2024, this market is likely to increase to US$51.9 bn by the end of the forecast period. The prevalence of leukemia has been higher than lymphoma and myeloma. The trend is expected to remain so with the leukemia segment occupying nearly 50% of the overall market for hematological malignancies by 2024.

A regional analysis of the worldwide market for hematological malignancies has also been offered in this research report. According to the study, North America, the Middle East and Africa, Latin America, Europe, and Asia Pacific are the main regional markets for hematological malignancies across the world. In 2015, North America acquired the leading position in this market and was closely followed by Europe. The high prevalence of hematological cancers, together with state-of-art diagnostic technologies and increased awareness level of people, propelled the hematological malignancies significantly in both the regions.

Progressing at a CAGR of 6.80%, North America is likely to retain its leadership over the forecast period. The presence of an advanced healthcare infrastructure is likely to support this regional market to register a steady rise in the near future. Apart from this, the Asia Pacific market for hematological malignancies is also projected to witness strong growth over the next few years, owing to the existing rich pipeline and the imminent launch of targeted therapies during the forecast period, states the research report.

Request to view Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4580

The sedentary and unhealthy lifestyle of people across the world has exposed them to a number of lifestyle-related diseases, hematological malignancies being a prominent one of them. The National Cancer Institute has stated that hematological cancer is the fifth most common cancer among people, globally, and is likely to record increased prevalence over the next few years. “With the upswing in the cases of hematological malignancies, the demand for their treatment is registering a tremendous rise, leading to a remarkable surge in the global market for hematological malignancies,” says an analyst at TMR.

In addition to this, the technological advancements in diagnostic procedures and the growing awareness level are projected to encourage people to go for diagnostic tests, which is likely to influence this market substantially in the near future. However, high costs of branded drugs and the absence of favorable reimbursement policies in emerging nations may hamper this market from growing steadily in the years to come, notes the study.

Request to Download TOC of the Report: http://www.transparencymarketresearch.com/report-toc/4580

With the presence of a few but prominent players, such as Celgene, Roche, Novartis, and AbbVie, the global hematological malignancies market demonstrates an intensely competitive landscape. These four players collectively accounted for more than 58% of the overall market in 2015. Currently, they are focusing aggressively on expanding their distribution networks and geographical operations across Asia Pacific, Latin America, and the Middle East and Africa. Researchers expect the leading companies in this market to engage in mergers and acquisitions over the forthcoming years in a bid to bring about product differentiation to combat the competition.

Global Hematological Malignancies Market Report is available @ US$ 5795 : http://www.transparencymarketresearch.com/checkout.php?rep_id=4580<ype=S

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hematological Malignancies Market Research Report by Key Players Analysis 2024 here

News-ID: 721887 • Views: 59

More Releases from Transparency Market Research

Osteoporosis Drugs Market Companies Analysis, Advancement and Precise Outlook …
Transparency Market Research (TMR) has published a new report titled, ‘Osteoporosis Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’. According to the report, the global Osteoporosis Drugs market was valued at US$ 11.5 Bn in 2018 and is projected to contract at a CAGR of 0.3% from 2019 to 2027. Overview Osteoporosis is a chronic and life-threatening disease, in which microstructure of bones is altered due to
Remote Patient Monitoring Devices Market News Research Report 2020
The global remote patient monitoring devices market is foreseen in a report by Transparency Market Research (TMR) to show a decently consolidated nature coupled with intense competition between key players. Recently, a larger aggregate share was held by a few prominent names of the market. F. Hoffmann-La Roche Ltd., AMD Global Telemedicine, and Honeywell HomMed LLC are some of the leading companies operating in the market. Merger and acquisition could
Oxygen Therapy Devices Market is Thriving Worldwide By Size, Revenue, Emerging T …
The demand within the global oxygen therapy devices market is projected to increase as improved medical procedures make their way into the healthcare industry. Towards the end of last year, a group of high-school students became victims of gas poisoning across a large building in Suwon. The absence of proper medical equipment for oxygen therapy became a matter of regional outrage. In this review, Transparency Market Research (TMR) looks into
Covid-19 Impact on Organic Turmeric Market: Present Scenario and Future Growth P …
The report details an exhaustive account of the global organic turmeric market along with numerous associated factors. Some of these factors that are included in the report are drivers, restraints, competitive analysis, latest trends and opportunities, geographical outlook, and many other aspects. The study covered in the report spans a forecast period from 2018 to 2026. From an overall perspective, the report is expected to exist as a valuable insight

All 5 Releases


More Releases for Hematological

Hematological Malignancies Market to Reach 7.50% by 2024
Global Hematological Malignancies Market: Snapshot Hematological malignancies, commonly known as hematological cancer, is registering a widespread prevalence across the world. According to the National Cancer Institute, hematological cancer is the fifth most commonly occurring cancer, globally, and is the second prominent reason behind the cancer death in the U.S. Researchers expect the incidence of hematological malignancies to increase further in the coming years, which will result in the growing need for
Advanced Technologies Of Hematological Disorders Market 2017
Albany, NY, 23rd November : Recent research and the current scenario as well as future market potential of "Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need" globally. The hematological disorders therapy area encompasses non-malignant disorders of the blood such as anemia, sickle cell disease, neutropenia and hemophilia. Get PDF for
Hematological Cancers Market 2017 Trends and Review
The Global Hematological Cancers Market Research Report 2017 to 2022 renders deep perception of the key regional market status of the Hematological Cancers Industry on a global level that primarily aims the core regions which comprises of continents like Europe, North America, and Asia and the key countries such as United States, Germany, China and Japan. Request for sample of Hematological Cancers Market research report @ https://goo.gl/BeUKBz Split by product type,
Hematological Malignancies Market Is Expected To Profits
Global Hematological Malignancies Market: Snapshot Hematological malignancies, commonly known as hematological cancer, is registering a widespread prevalence across the world. According to the National Cancer Institute, hematological cancer is the fifth most commonly occurring cancer, globally, and is the second prominent reason behind the cancer death in the U.S. Researchers expect the incidence of hematological malignancies to increase further in the coming years, which will result in the growing need for
Hematological Malignancies Market grows with growing prevalence of hematological …
The global hematological malignancies market is highly competitive in nature and is characterized by a consolidated nature, owing to the presence of a few players holding a large share of the overall market, states a research study by Transparency Market Research. The leading players operating in the global market, including Roche, Celgene, Novartis, and AbbVie are anticipated to remain dominant throughout the forecast period. In order to maintain their position
Hematological Cancers Market Review with Comparative Analysis
Hematological cancer, commonly known as hematological malignancy, is a class of cancer that affects the lymph nodes, blood, and bone marrow. It includes numerous forms such as lymphoma, leukemia, and myeloma. Leukemia is a malignancy in which abnormal white blood cells are formed in the bone marrow. Lymphoma is a blood cancer that develops in the lymphatic system. Myeloma is a cancer associated with the plasma of the white blood